No Data
No Data
Positive Outlook for Axsome Therapeutics: Buy Rating Backed by Promising AXS-05 Prospects
Axsome Therapeutics: Promising Growth Trajectory Justifies Buy Rating Amidst Auvelity's Commercial Success
Express News | Axsome Therapeutics Inc : Mizuho Raises Target Price to $124 From $106
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Ladenburg Thalmann Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $175
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Madrigal Pharmaceuticals (MDGL)
No Data